Compare Cassava Sciences Inc (FLNA) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wix.Com Ltd — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Wix.Com Ltd trades at $74.13 (market cap $3.11B). The key difference: Wix.Com Ltd is far larger — about 78.9× Cassava Sciences Inc's market cap, and Wix.Com Ltd is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Wix.Com Ltd for 62 Days on average.
| FLNA | WIX | |
|---|---|---|
Market Cap | $39.40M | $3.11B |
Volume | 759,018 | 809,286 |
Sector | Health | Technology |
52-Week High | $4.64 | $145.54 |
52-Week Low | $0.68 | $40.43 |
Typical Hold Time | 37 Days | 62 Days |
Enterprise Value | -$43.28M | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Wix stock trades at $72.97, down 1.27% today, amid a bearish technical signal and mixed earnings. Recent quarters show volatility with a Q1 2026 miss but a Q2 beat. Revenue growth is solid, reaching $1.99B in 2025, but profitability remains weak with a negative net income margin. The stock faces headwinds from a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026.
The outlook is cautious; analyst consensus is bullish with a $77 price target, but high valuation ratios and legal risks offset growth potential. Investors should weigh strong revenue trends against profitability challenges and near-term sentiment pressure from litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
